Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2023.

• In Q1 2023, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million; the TTM figure through Mar 2023 stood at $1.4 million (down 87.46% YoY), while the FY2022 annual figure was $4.5 million, down 63.92% from the prior year.
• Current Deferred Revenue was $1.4 million for Q1 2023 at Revolution Medicines, down from $4.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.4 million in Q1 2020 to a low of $609000.0 in Q4 2019.
• Historically, Current Deferred Revenue has averaged $9.8 million across 5 years, with a median of $10.7 million in 2021.
• The sharpest annual moves came in 2020 and 2023: Current Deferred Revenue surged 1888.67% in 2020, then tumbled 87.46% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $609000.0 in 2019, then soared by 1888.67% to $12.1 million in 2020, then grew by 2.04% to $12.4 million in 2021, then tumbled by 63.92% to $4.5 million in 2022, then sank by 67.84% to $1.4 million in 2023.
• The last three Current Deferred Revenue figures came in at $1.4 million (Q1 2023), $4.5 million (Q4 2022), and $9.7 million (Q3 2022), per Business Quant data.